يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"Chandroday Biswas"', وقت الاستعلام: 0.84s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer

    المؤلفون: Komal Jhaveri, Joyce O’Shaughnessy, Peter A. Fasching, Sara M. Tolaney, Denise A. Yardley, Vikash Kumar Sharma, Chandroday Biswas, Astrid Thuerigen, Purnima Pathak, Hope S. Rugo

    المصدر: Therapeutic Advances in Medical Oncology, Vol 15 (2023)

    مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    وصف الملف: electronic resource

    Relation: https://doaj.org/toc/1758-8359

    URL الوصول: https://doaj.org/article/f9fa04a73b63440b97588ebecf3c53a7

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  2. 2
    Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial

    المؤلفون: Victoria Federico Paly, Laura Amanda Vallejo-Aparicio, Alan Martin, José Luis Izquierdo, Juan Antonio Riesco, Juan José Soler-Cataluña, Catarina Abreu, Chandroday Biswas, Afisi S Ismaila

    المصدر: International Journal of Chronic Obstructive Pulmonary Disease. 17:3097-3109

    مصطلحات موضوعية: Drug Combinations, Pulmonary Disease, Chronic Obstructive, Spain, Cost-Benefit Analysis, Nebulizers and Vaporizers, Administration, Inhalation, Humans, Fluticasone, General Medicine, International Journal of Chronic Obstructive Pulmonary Disease, Chlorobenzenes, Benzyl Alcohols

    وصف الملف: text/html

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4148a717e2cb462504082f15f79f9ce9
    https://doi.org/10.2147/copd.s366765

    PDF full text from Publisher Find this article in full text from ProQuest
    أضف إلى المفضلة
  3. 3
    Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2

    المؤلفون: David Cameron, Vikash Kumar Sharma, Chandroday Biswas, Cathy Clarke, David Chandiwana, Purnima Pathak

    المصدر: Cameron, D A, Kumar Sharma, V, Biswas, C, Clarke, C, Chandiwanna, D & Pathak, P 2023, ' Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2 ', Journal of Medical Ethics . https://doi.org/10.1080/13696998.2023.218205

    مصطلحات موضوعية: Health Policy

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d029006b4975578645d5ad73d861316
    https://hdl.handle.net/20.500.11820/b270052c-1c48-43fa-bf9b-4c44f8cad630

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء